Session: 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II
Hematology Disease Topics & Pathways:
Research, MDS, MPN, Health outcomes research, Clinical Research, Chronic Myeloid Malignancies, CMML, Diseases, Myeloid Malignancies
Clonal cytopenia of undetermined significance (CCUS), a precursor of myeloid neoplasms (MN), is characterized by one or more persistent cytopenias, and acquired mutations in myeloid malignancy-associated genes. ZRSR2, located at Xp22.2, is one of the MN-associated genes and a member of the spliceosome family of genes.
Aim:
Describe the clinical characteristics, pattern of progression, and genetics of ZRSR2 mutation (ZRSR2m)-harboring CCUS patients.
Methods:
Next-generation sequencing (NGS) was performed for 9320 patients between 2016-2023 at Mayo Clinic. After obtaining IRB approval, clinical characteristics and results of bone marrow morphology, cytogenetics, and molecular studies were abstracted. Overall Survival (OS) was calculated using Kaplan-Meier, from the date of NGS until death or last follow-up. The ZRSR2m MN control cohort included 125 patients with myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and MDS/MPN overlap. BlueSky Statistics V10.3.1 was used for statistical analysis.
Results:
ZRSR2m was detected in 39 CCUS patients, all of whom were males. Concurrent hematological neoplasms were identified in 8 patients (21%). Five (13%) had plasma cell proliferative disorders including 3 multiple myeloma, 1 MGUS, and 1 AL amyloidosis. There were also 2 patients with chronic lymphocytic leukemia and 1 with VEXAS syndrome. Prior chemotherapy, with or without radiotherapy, was given to 4 patients (10.3%), whereas 13 patients (33%) had received previous immunotherapy. Abnormal cytogenetics were detected in 11 patients (29%), with the most common abnormality being +8 (n=5, 13%). In 23 patients (59%), an absolute monocyte count of ≥0.5 x 10^9/L was documented which could be classified as clonal cytopenia with monocytosis of unknown significance (CCMUS).
ZRSR2 median gender-corrected VAF among CCUS patients was 32% (range, 1-45). Isolated ZRSR2m was found in 6 patients (15%), and 1 (3%) had multiple ZRSR2m. The median number of co-mutations was 1 (range, 0-3). Sequential NGS, available in 13 patients, showed that 1 patient developed 3 ZRSR2 mutations and 2 ZRSR2 VUS. TET2 was the most common co-mutation (n=25, 64%). Additionally, TET2 was an isolated co-mutation in 18 patients (46%). ASXL1 co-mutation was the second most common (n=8, 20.5%), while other less common co-mutations were IDH1, IDH2, SRSF2, SF3B1, TP53, GATA2, and KDM6A. Pre-ZF1 was the most commonly mutated region in ZRSR2 mutations (n=23, 59%).
With a median follow-up of 32 months, 9 (23%) of the ZRSR2m CCUS patients progressed to MNs, none progressed to AML. Five (55.6%) progressed to MDS, 4 were subclassified as low blast (LB) and 1 as increased blast-1 (IB1). Four (44.4%) progressed to MDS/MPN overlap syndrome, with 3 subclassified as chronic myelomonocytic leukemia (CMML). None of the patients with isolated ZRSR2m progressed to MDS or CMML. None of the patients who received prior immunotherapy progressed to MDS.
Thirty-six (92.3%) patients had high-risk CCUS (Malcovati et al, Blood 2017) while 3 had intermediate risk with no low-risk patients. None of the intermediate-risk patients progressed to MDS, while 5 patients of the high-risk (13.9%) progressed to MDS (p=1).
Twelve (31%) patients died, and the median overall survival (mOS) was 56 months. Higher hemoglobin levels improved OS (HR=0.59, p=0.02), while higher adjusted ZRSR2 VAF worsened OS (HR=1.05, p=0.017). Patients with TET2 as isolated co-mutations showed better mOS than the rest of the cohort (not reached vs 41 months, p= 0.03). ZRSR2m CCUS patients showed a trend suggestive of better mOS than ZRSR2m with MNs including AML (56 vs 30 months, p=0.14), and with excluding AML (56 vs 39 months, p=0.24). On multivariate analysis, both Hgb (HR=0.61, p=0.03) and isolated TET2 co-mutation (HR=0.19, p=0.04) retained statistical significance. mOS was not affected by prior history of treatment, number of co-mutations, isolated ZRSR2, ASXL1 co-mutation, or MDS progression.
Conclusion:
ZRSR2m CCUS cohort was exclusively males. There was a significant number of patients with concurrent hematological malignancy or a history of prior chemo- and/or immuno-therapy (36%). Most patients had high-risk CCUS but showed a low rate of progression to MNs, especially in those with isolated ZRSR2. Additionally, patients with isolated TET2 co-mutation had better survival, indicating that TET2 confers a favorable prognosis among ZRSR2m CCUS patients.
Disclosures: Mangaonkar: BMS: Research Funding; Incyte: Research Funding; Novartis: Research Funding. Patnaik: Polaris: Research Funding; Epigenetix: Research Funding; Solu therapeutics: Research Funding; Kura Oncology: Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees; StemLine: Research Funding.
See more of: Oral and Poster Abstracts